Directorate Change

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR
THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014

Tiziana Life Sciences plc
(“Tiziana” or the “Company”)

Directorate Change

New York/London, 7 February 2019 – Tiziana Life
Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company
focusing on the discovery and development of innovative therapeutics for
inflammation and oncology indications, today announces that Riccardo
Dalla-Favera MD has resigned from his role as Non-Executive Director of
the Company. The Company is grateful to Dr Favera for his time,
expertise and commitment to the Company.

The person who arranged for release of this announcement on behalf of
the Company was Tiziano Lazzaretti, Chief Financial Officer of the
Company.

About Tiziana Life Sciences

Tiziana is a UK biotechnology company that focuses on the discovery
and development of novel molecules to treat human disease in oncology
and immunology. In addition to milciclib, the Company is also developing
Foralumab for liver diseases. Foralumab is the only fully human
anti-CD3 mAbs in clinical development in the world. This compound has
potential application in a wide range of autoimmune and inflammatory
diseases, such as nonalcoholic steatohepatitis (NASH), primary biliary
cholangitis (PBS), ulcerative colitis, multiple sclerosis, type-1
diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and
rheumatoid arthritis, where modulation of a T-cell response is
desirable.

For more information go to http://www.tizianalifesciences.com

Contacts: